BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus [Yahoo! Finance]
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema